Very good benefit-to-risk profile with PCSK9 inhibitor in high risk ACS patients in ODYSSEY OUTCOMES trial

Name: Very good benefit-to-risk profile with PCSK9 inhibitor in high risk ACS patients in ODYSSEY OUTCOMES trial
Uploaded: 2018-03-10T04:00:00+00:00
Duration: 3 min 17 s
Description: ACC 2018 Prof. Gabriel Steg discusses the 15% reduction of MACE obtained with alirocumab, with a good safety profile. The observed CV benefit was greater i

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

APOC3 Inhibition in FCS and Severe Hypertriglyceridemia
APOC3 Inhibition in FCS and Severe Hypertriglyceridemia
Hyperlipidemia
APOC3 Inhibition in FCS and Severe Hypertriglyceridemia
Erik Stroes
- Erik Stroes
Primary Care Takeaways From VESALIUS-CV: Evolocumab Efficacy in Patients Without Significant Atherosclerosis
Primary Care Takeaways From VESALIUS-CV: Evolocumab Efficacy in Patients Without Significant Atherosclerosis
Cardiology
Primary Care Takeaways From VESALIUS-CV: Evolocumab Efficacy in Patients Without Significant Atherosclerosis
Javier Morales, MD, FACP, FACE
- Javier Morales, MD, FACP, FACE
Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
ACC 2026 Clinical Insights: Advancing Cardiovascular Care
Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
Nicholas Marston, MD
- Nicholas Marston, MD
Real-World Impact of Evolocumab on MACE Reduction in ASCVD
Real-World Impact of Evolocumab on MACE Reduction in ASCVD
Hyperlipidemia
Real-World Impact of Evolocumab on MACE Reduction in ASCVD
Nihar R. Desai, MD, MPH
- Nihar R. Desai, MD, MPH

Very good benefit-to-risk profile with PCSK9 inhibitor in high risk ACS patients in ODYSSEY OUTCOMES trial

Recommended

Title